Evidence map›Paper›PMID 29209143›Full record

ReviewInternational journal of biological sciences2017

Risk Factors and Preventions of Breast Cancer.

Yi-Sheng Sun, Zhao Zhao, Zhang-Nv Yang, Fang Xu, Hang-Jing Lu, Zhi-Yong Zhu, Wen Shi, Jianmin Jiang, Ping-Ping Yao, Han-Ping Zhu

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of biological sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 759 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
759citing papers in PubMed, 7 pooled it
46.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05771454 completednot on this mapstarted 2023, after this paper: background citation

Frequency of Occult Breast Cancer After Prophylactic Mastectomy Among High-Penetrance Breast Cancer Gene Positives; Future Implications on Sentinel Lymph Node Biopsy in LMIC: A Single-center Cross-sectional Study

TypeobservationalSponsorAga Khan University Hospital, PakistanRan2023 to 2023Enrolled26ConditionsGenetic Predisposition, BRCA Mutation, Breast Cancer, Occult CancerArmsHistopathological confirmation
NCT06357689 completednot on this mapstarted 2021, after this paper: background citation

Studying the Association of Genetic Variations in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population

TypeobservationalSponsorAin Shams UniversityRan2021 to 2023Enrolled417ConditionsBreast Cancer
3 · Its place in the literature

Who cites it

759 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,950 citations in OpenAlex.

  1. Mastitis as a risk factor for breast cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. The Increasing Importance of Breast Cancer in the United Arab Emirates.Asia-Pacific journal of clinical oncology · 2026
    Review
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Article
  17. Breast cancer diagnosis as a window of opportunity for smoking cessation: analysis of changes in smoking behaviour in 736 smoking breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  18. Article
  19. Review
  20. Article

699 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yi-Sheng SunKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhao ZhaoCentre of Laboratory Medicine, Zhejiang Provincial People's Hospital.
Zhang-Nv YangKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Fang XuKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Hang-Jing LuKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhi-Yong ZhuKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Wen ShiKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Jianmin JiangKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Ping-Ping YaoKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Han-Ping ZhuKey Lab of Vaccine against Hemorrhagic Fever with Renal Syndrome, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Zhejiang Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the second leading cause of cancer deaths among women. The development of breast cancer is a multi-step process involving multiple cell types, and its prevention remains challenging in the world. Early diagnosis of breast cancer is one of the best approaches to prevent this disease. In some developed countries, the 5-year relative survival rate of breast cancer patients is above 80% due to early prevention. In the recent decade, great progress has been made in the understanding of breast cancer as well as in the development of preventative methods. The pathogenesis and tumor drug-resistant mechanisms are revealed by discovering breast cancer stem cells, and many genes are found related to breast cancer. Currently, people have more drug options for the chemoprevention of breast cancer, while biological prevention has been recently developed to improve patients' quality of life. In this review, we will summarize key studies of pathogenesis, related genes, risk factors and preventative methods on breast cancer over the past years. These findings represent a small step in the long fight against breast cancer.

Indexed as

AnimalsBreast NeoplasmsFemaleHumansQuality of LifeRisk Factorsbreast cancerpathogenesisprevention.risk factor

Identifiers

PMID29209143
PMCPMC5715522
OpenAlexW2770397194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.